Neurelis Inc Drug Patent Portfolio

Neurelis Inc owns 1 orange book drug protected by 7 US patents Given below is the list of Neurelis Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11241414 Administration of benzodiazepine compositions 27 Mar, 2029
Active
US11793786 Administration of benzodiazepine compositions 27 Mar, 2029
Active
US8895546 Administration of benzodiazepine compositions 27 Mar, 2029
Active
US9763876 Administration of benzodiazepine compositions 27 Mar, 2029
Active
US8927497 Absorption enhancers for intranasal administration 21 Jul, 2025
Active
US10265402 Absorption enhancers for drug administration 11 May, 2025
Active
US9642913 Pharmaceutical composition including alkyl glycoside and an anti-seizure agent 11 May, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Neurelis Inc.

Activity Date Patent Number
Patent litigations
Recordation of Patent Grant Mailed 24 Oct, 2023 US11793786
Email Notification 24 Oct, 2023 US11793786
Mail Patent eGrant Notification 24 Oct, 2023 US11793786
Recordation of Patent eGrant 24 Oct, 2023 US11793786
Patent eGrant Notification 24 Oct, 2023 US11793786
Patent Issue Date Used in PTA Calculation 24 Oct, 2023 US11793786
Email Notification 05 Oct, 2023 US11793786
Issue Notification Mailed 04 Oct, 2023 US11793786
Dispatch to FDC 19 Sep, 2023 US11793786
Application Is Considered Ready for Issue 19 Sep, 2023 US11793786
Miscellaneous Incoming Letter 13 Sep, 2023 US11793786
Issue Fee Payment Verified 13 Sep, 2023 US11793786
Issue Fee Payment Received 13 Sep, 2023 US11793786
Email Notification 29 Aug, 2023 US11793786
Mail Examiner Interview Summary (PTOL - 413) 29 Aug, 2023 US11793786


Neurelis Inc's Drug Patent Litigations

Neurelis Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 29, 2019, against patent number US9763876. The petitioner Aquestive Therapeutics, Inc. formerly Monosol RX, LLC, challenged the validity of this patent, with Neurelis, Inc. as the respondent. Click below to track the latest information on how companies are challenging Neurelis Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9763876 January, 2019 FWD Entered
(06 Aug, 2020)
Neurelis, Inc. Aquestive Therapeutics, Inc. formerly Monosol RX, LLC
US9763876 January, 2019 Terminated-Denied
(01 Aug, 2019)
Neurelis, Inc. Aquestive Therapeutics, Inc. formerly Monosol RX, LLC
US9763876 January, 2019 Terminated-Denied
(01 Aug, 2019)
Neurelis, Inc. Aquestive Therapeutics, Inc. formerly Monosol RX, LLC


Neurelis Inc's Family Patents

Neurelis Inc drugs have patent protection in a total of 28 countries. It's US patent count contributes only to 45.9% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Neurelis Inc Drug List

Given below is the complete list of Neurelis Inc's drugs and the patents protecting them.


1. Valtoco

Valtoco is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11241414 Administration of benzodiazepine compositions 27 Mar, 2029
(4 years from now)
Active
US11793786 Administration of benzodiazepine compositions 27 Mar, 2029
(4 years from now)
Active
US8895546 Administration of benzodiazepine compositions 27 Mar, 2029
(4 years from now)
Active
US9763876 Administration of benzodiazepine compositions 27 Mar, 2029
(4 years from now)
Active
US8927497 Absorption enhancers for intranasal administration 21 Jul, 2025
(9 months from now)
Active
US10265402 Absorption enhancers for drug administration 11 May, 2025
(6 months from now)
Active
US9642913 Pharmaceutical composition including alkyl glycoside and an anti-seizure agent 11 May, 2025
(6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valtoco's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List